T-cells attacking cancer cell illustration of microscopic photos

Silence Therapeutics

LN: SLN

Market Cap£560.5m

Last Close 625p

Silence Therapeutics (SLN) has a portfolio of siRNA drugs in early stage testing. SLN124 for iron overload was recently dosed in the first volunteers of a Phase I study. SLN360 is being developed for cardiovascular disease and its IND was recently approved.

More Silence Therapeutics content >

Investment summary

Silence Therapeutics is a developer of RNA-based therapeutics with some of the foundational intellectual property in the space. The value of its platform has been highlighted with recent licensing deals with Mallinckrodt to develop a complement inhibitor, with Takeda to research undisclosed targets, and recently with AstraZeneca to research cardiovascular, renal, metabolic and respiratory targets. This is in addition to the company’s internal pipeline; SLN124 and SLN360 both recently began enrolling patients into Phase I studies.

Y/E Dec
Revenue (£m)
EBITDA (£m)
PBT (£m)
EPS (fd) (p)
P/E (x)
P/CF (x)
2018A 0.0 (20.2) (19.8) (25.18) N/A N/A
2019A 0.2 (22.3) (22.3) (27.15) N/A N/A
2020E 6.3 (23.0) (20.5) (20.93) N/A N/A
2021E 10.0 (22.5) (20.9) (20.96) N/A N/A
Industry outlook

RNA therapeutics is an increasingly high-profile sector of the biotechnology industry, now with multiple drug approvals for a range of disorders. We consider the technology in this field to be mature and expect increased interest across the industry to develop new drugs of this class.

Last updated on 21/06/2021
Content on Silence Therapeutics
Silence Therapeutics – Change is good
Healthcare | Update | 17 September 2020
cells
Executive interview – Silence Therapeutics
Healthcare | Edison TV | 9 April 2020
View more
Register to receive research on Silence Therapeutics as it is published
Share price graph
Balance sheet
Forecast net debt (£m) 0
Forecast gearing ratio (%) 0
Price performance
%
1m
3m
12m
Actual (1.6) 10.8 49.5
Relative* (2.2) 5.3 29.5
52-week high/low 649.0p/339.0p
*% relative to local index
Key management
Rob Quinn CFO
Gem Hopkins Head of IR
Iain Ross Executive Chairman